AstraZeneca Says Updated Durvalumab Data Confirms Results

LONDON (Alliance News) - AstraZeneca PLC on Friday released updated data from a phase I/II trial ...

Alliance News 17 February, 2017 | 5:22PM
Email Form

LONDON (Alliance News) - AstraZeneca PLC on Friday released updated data from a phase I/II trial of durvalumab in locally-advanced or metastatic urothelial cancer.

This updated data, which was presented at the 2017 ASCO Genitourinary Cancers Symposium, demonstrated "compelling clinical activity" in patients who had previously progressed during or after one line of standard platinum-based chemotherapy, AstraZeneca said.

"The durable responses observed in this larger data set from Study 1108 confirm the promising efficacy we've already seen for durvalumab in patients with advanced bladder cancer. We are continuing to test durvalumab in combination with tremelimumab and as monotherapy in the bladder cancer 1st-line setting in our ongoing Phase III DANUBE trial," said Head of Oncology Innovative Medicines at MedImmune David Berman in a statement.

MedImmune is AstraZeneca's biologics research and development arm. Shares in AstraZeneca closed up 1.8% at 4,607.62 pence on Friday.

By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews

Copyright 2017 Alliance News Limited. All Rights Reserved.

Email Form
Securities Mentioned in Article
Security Name Price Change (%) Morningstar Rating
AstraZeneca PLC 4,562.00 GBX -0.18
About Author Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.